rs587783807
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1
This summary comes from the ClinGen Evidence Repository: The c.1702A>G variant in MTM1 is a missense variant predicted to cause substitution of isoleucine by valine at amino acid 568. The highest population filtering allele frequency in gnomAD v4.1.0 is 0.00002629 (33/895101 alleles, 9 hemizygotes) in European (non-Finnish) population, which is higher than the ClinGen Congenital Myopathies VCEP threshold (≥0.000016) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.212, which is neither above nor below the thresholds predicting a damaging or benign impact on MTM1 function. In summary, this variant meets the criteria to be classified as benign for X-linked centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: BA1. (Congenital Myopathies VCEP specifications version 1; 8/7/2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA172597/MONDO:0018947/149
Frequency
Consequence
NM_000252.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MTM1 | NM_000252.3 | c.1702A>G | p.Ile568Val | missense_variant | 15/15 | ENST00000370396.7 | NP_000243.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MTM1 | ENST00000370396.7 | c.1702A>G | p.Ile568Val | missense_variant | 15/15 | 1 | NM_000252.3 | ENSP00000359423.3 |
Frequencies
GnomAD3 genomes AF: 0.0000180 AC: 2AN: 110829Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 32995
GnomAD3 exomes AF: 0.0000491 AC: 9AN: 183296Hom.: 0 AF XY: 0.0000295 AC XY: 2AN XY: 67760
GnomAD4 exome AF: 0.0000301 AC: 33AN: 1098164Hom.: 0 Cov.: 31 AF XY: 0.0000248 AC XY: 9AN XY: 363526
GnomAD4 genome AF: 0.0000180 AC: 2AN: 110829Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 32995
ClinVar
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Severe X-linked myotubular myopathy Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 17, 2024 | - - |
Centronuclear myopathy Benign:1
Benign, reviewed by expert panel | curation | ClinGen Congenital Myopathies Variant Curation Expert Panel, ClinGen | Aug 07, 2024 | The c.1702A>G variant in MTM1 is a missense variant predicted to cause substitution of isoleucine by valine at amino acid 568. The highest population filtering allele frequency in gnomAD v4.1.0 is 0.00002629 (33/895101 alleles, 9 hemizygotes) in European (non-Finnish) population, which is higher than the ClinGen Congenital Myopathies VCEP threshold (≥0.000016) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.212, which is neither above nor below the thresholds predicting a damaging or benign impact on MTM1 function. In summary, this variant meets the criteria to be classified as benign for X-linked centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: BA1. (Congenital Myopathies VCEP specifications version 1; 8/7/2024) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at